Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of the HLA-B27 antigen is notably diminished in ankylosing spondylitis (AS) associated with IBD, but is heightened in concurrent sacroiliitis. Similarly, certain polymorphisms of endoplasmic reticulum aminopeptidase (ERAP-1) appear to be involved. Carriage of variant NOD2/CARD15 polymorphisms has been demonstrated to correlate with the risk of subclinical intestinal inflammation in AS. Biomarkers indicative of pro-inflammatory activity, including C-reactive protein (CRP) along with erythrocyte sedimentation rate (ESR), are among the consistent predictive biomarkers of disease progression. Nevertheless, these markers are not without limitations and exhibit relatively low sensitivity. Other promising markers encompass IL-6, serum calprotectin (s-CLP), serum amyloid (SAA), as well as biomarkers regulating bone formation such as metalloproteinase-3 (MMP-3) and Dickkopf-related protein 1 (DKK-1). Additional candidate indicators of structural changes in SpA patients include matrix metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF), tenascin C (TNC), and CD74 IgG. Fecal caprotein (f-CLP) levels over long-term follow-up of AS patients have demonstrated predictive value in anticipating the development of IBD. Serologic antibodies characteristic of IBD (ASCA, ANCA) have also been compared; however, results exhibit variability. In this review, we will focus on biomarkers associated with both axial SpA and idiopathic intestinal inflammation, notably enteropathic spondyloarthritis.

• MeSH
• ankylózující spondylitida krev   diagnóza   imunologie   MeSH
• axiální spondyloartritida krev   diagnóza   MeSH
• biologické markery * krev   MeSH
• C-reaktivní protein analýza   metabolismus   MeSH
• HLA-B27 antigen genetika   imunologie   MeSH
• idiopatické střevní záněty * krev   imunologie   diagnóza   komplikace   MeSH
• leukocytární L1-antigenní komplex krev   MeSH
• lidé MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

BACKGROUND: Adipose tissue is significantly involved in inflammatory bowel disease (IBD). Vitamin D can affect both adipogenesis and inflammation. The aim of this study was to compare the production of selected adipokines, potentially involved in the pathogenesis of IBD - adiponectin, resistin, retinol binding protein 4 (RBP-4), adipocyte fatty acid binding protein and nesfatin-1 in children with IBD according to the presence of 25-hydroxyvitamin D (25(OH)D) deficiency. METHODS: The study was conducted as a case-control study in pediatric patients with IBD and healthy children of the same sex and age. In addition to adipokines and 25(OH)D, anthropometric parameters, markers of inflammation and disease activity were assessed in all participants. RESULTS: Children with IBD had significantly higher resistin levels regardless of 25(OH)D levels. IBD patients with 25(OH)D deficiency only had significantly lower RBP-4 compared to healthy controls and also compared to IBD patients without 25(OH)D deficiency. No other significant differences in adipokines were found in children with IBD with or without 25(OH)D deficiency. 25(OH)D levels in IBD patients corelated with RBP-4 only, and did not correlate with other adipokines. CONCLUSIONS: Whether the lower RBP-4 levels in the 25(OH)D-deficient group of IBD patients directly reflect vitamin D deficiency remains uncertain. The production of other adipokines does not appear to be directly related to vitamin D deficiency.

• MeSH
• adipokiny * krev   MeSH
• adiponektin krev   nedostatek   MeSH
• biologické markery krev   MeSH
• dítě MeSH
• DNA vazebné proteiny krev   MeSH
• idiopatické střevní záněty krev   komplikace   MeSH
• lidé MeSH
• mladiství MeSH
• nedostatek vitaminu D * komplikace   krev   MeSH
• nukleobindiny krev   MeSH
• plazmatické proteiny vázající retinol metabolismus   analýza   MeSH
• proteiny vázající mastné kyseliny krev   MeSH
• proteiny vázající vápník krev   MeSH
• resistin krev   MeSH
• studie případů a kontrol MeSH
• vitamin D * krev   analogy a deriváty   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

Cíl studie: Ověřit shodu výsledků měření koncentrace infliximabu a adalimumabu metodou point-of-care systém ProciseDx s koncentracemi stanovenými enzymovou imunoanalýzou (ELISA). Metody: Srovnali jsme 23 koncentrací infliximabu (IFX) a 22 koncentrací adalimumabu (ADL) změřených pomocí point-of-care (POCT) systému ProciseDx, založeného na Försterově principu rezonančního přenosu energie (FRET) s výsledky, které byly získány standardním vyšetřením enzymovou imunoanalýzou (ELISA) v klinické laboratoři. Výsledky: Spearmanův korelační koeficient u IFX je r = 0,9400 (p = 0,0001) a vážená Cohenova kappa 0,93 svědčí pro dobrou korelaci dat naměřených dvěma odlišnými měřicími systémy. Stejně výborné korelace hodnot bylo dosaženo i v případě ADL, kde r = 0,9098 (p = 0,0001), vážená Cohenova kappa 0,834. Závěr: POCT systém ProciseDx se ukázal jako vysoce spolehlivá metoda měření sérových hladin biologik IFX a ADL u pacientů s IBD. Jeho jednoduchá obslužnost a rychlost měření přináší zefektivnění biologické léčby a snížení finanční náročnosti této terapie.

Aim of the study: To verify whether the results of infliximab and adalimumab concentration measurements by the point-of-care method ProciseDx correspond with the concentrations determined by enzyme-linked immunosorbent assay (ELISA). Methods: Twenty-three infliximab (IFX) and twenty-two adalimumab (ADL) concentrations were compared. IFX and ADL trough levels were measured by the ProciseDx point-of-care (POCT) system based on the Förster resonance energy transfer (FRET) principle, and by standard immunoassay (ELISA) in a clinical laboratory. Results: Spearman‘s correlation coefficient for IFX R = 0.9400 (P = 0.0001) and the weighted Cohen‘s kappa of 0.93 indicate a good correlation between data measured by two different measurement systems. The same excellent correlation of values was achieved for ADL, where R = 0.9098 (P = 0.0001) and the weighted Cohen‘s kappa is 0.834. Conclusion: The ProciseDx POCT system is a highly reliable method for measuring serum trough IFX and ADL levels in IBD patients. It is easy to operate and fast, it brings more effectiveness to the IBD biological treatment and reduces financial and time burden of this therapy.

• MeSH
• adalimumab aplikace a dávkování   krev   terapeutické užití   MeSH
• biologická terapie MeSH
• dospělí MeSH
• ELISA MeSH
• idiopatické střevní záněty * farmakoterapie   krev   MeSH
• infliximab aplikace a dávkování   krev   terapeutické užití   MeSH
• klinické zkoušky jako téma MeSH
• lidé středního věku MeSH
• lidé MeSH
• monitorování léčiv * MeSH
• point of care testing * MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH

Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn's disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).

• MeSH
• biodiverzita MeSH
• dospělí MeSH
• feces mikrobiologie   MeSH
• houby genetika   MeSH
• idiopatické střevní záněty krev   farmakoterapie   mikrobiologie   chirurgie   MeSH
• inhibitory TNF terapeutické užití   MeSH
• interleukin-17 metabolismus   MeSH
• leukocyty mononukleární metabolismus   MeSH
• lidé MeSH
• metagenomika MeSH
• protilátky krev   MeSH
• RNA ribozomální 16S genetika   MeSH
• střevní mikroflóra * genetika   MeSH
• studie případů a kontrol MeSH
• stupeň závažnosti nemoci MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Objectives: Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD).Materials/methods: This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period.Results: A total of 173 patients were analysed. The mean BMI was 25.5 ± 5.1 and initial mean 25OHD level was 62.7 ± 25.5 nmol/l. A similar increase (9.7 ± 26.9 vs 9.8 ± 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p < .001) and negatively with the baseline 25OHD level (p < .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU.Conclusions: Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.

• MeSH
• aplikace orální MeSH
• cholekalciferol aplikace a dávkování   MeSH
• dospělí MeSH
• idiopatické střevní záněty krev   komplikace   MeSH
• lidé středního věku MeSH
• lidé MeSH
• logistické modely MeSH
• multivariační analýza MeSH
• nedostatek vitaminu D komplikace   farmakoterapie   MeSH
• prospektivní studie MeSH
• rozvrh dávkování léků MeSH
• tělesná hmotnost MeSH
• vitamin D analogy a deriváty   krev   MeSH
• vztah mezi dávkou a účinkem léčiva MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• Geografické názvy
• Česká republika MeSH

AIM: To evaluate the effects of orally administered gadolinium orthovanadate GdVO4:Eu3+ nanoparticles (VNPs) on the course of chronic carrageenan-induced intestinal inflammation. METHODS: Samples of small intestinal tissue were collected from four groups of rats (intact, after administration of VNPs, with carrageenaninduced intestinal inflammation, with carrageenan-induced intestinal inflammation orally exposed to VNPs) to assess the intestinal morphology and HSP90α expression. Levels of seromucoid, C-reactive protein, TNF-α, IL-1β and IL-10 were determined in blood serum. RESULTS: Oral exposure to VNPs was associated with neither elevation of inflammation markers in blood serum nor HSP90α overexpression in the small intestine, i.e. no toxic effects of VNPs were observed. Carrageenan-induced intestinal inflammation was accompanied by higher levels of TNF-α and IL-1β, as well as HSP90α upregulation in the intestinal mucosa, compared with controls. Administration of VNPs to rats with enteritis did not lead to statistically significant changes in concentrations of circulating pro-inflammatory cytokines with the trend towards their increase. CONCLUSION: No adverse effects were observed in rats orally exposed to VNPs at a dose of 20 μg/kg during two weeks. Using the experimental model of carrageenan-induced enteritis, it was demonstrated that VNPs at the dose used in our study did not affect the course of intestinal inflammation.

• MeSH
• C-reaktivní protein účinky léků   metabolismus   MeSH
• enterokolitida krev   chemicky indukované   patologie   MeSH
• gadolinium farmakologie   MeSH
• idiopatické střevní záněty krev   patologie   MeSH
• interleukin-10 krev   MeSH
• interleukin-1beta krev   účinky léků   MeSH
• karagenan toxicita   MeSH
• kovové nanočástice * MeSH
• krysa rodu rattus MeSH
• modely nemocí na zvířatech MeSH
• orosomukoid účinky léků   metabolismus   MeSH
• proteiny tepelného šoku HSP90 účinky léků   metabolismus   MeSH
• scavengery volných radikálů farmakologie   MeSH
• střevní sliznice účinky léků   metabolismus   patologie   MeSH
• TNF-alfa krev   účinky léků   MeSH
• vanadáty farmakologie   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu rattus MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH

OBJECTIVES: Therapeutic drug monitoring of thiopurine erythrocyte levels is not available in all centers and it usually requires quite a long time to obtain the results. The aims of this study were to build a model predicting low levels of 6-thioguanine and 6-methylmercaptopurine in pediatric inflammatory bowel disease (IBD) patients and to build a model to predict nonadherence in patients treated with azathioprine (AZA). METHODS: The study consisted of 332 observations in 88 pediatric IBD patients. Low AZA dosing was defined as 6-thioguanine levels <125 pmol/8 × 10 erythrocytes and 6-methylmercaptopurine levels <5700 pmol/8 × 10 erythrocytes. Nonadherence was defined as undetectable levels of 6-thioguanine and 6-methylmercaptopurine <240 pmol/8 × 10 erythrocytes. Data were divided into training and testing part. To construct the model predicting low 6-thioguanine levels, nonadherence, and the level of 6-thioguanine, the modification of random forest method with cross-validation and resampling was used. RESULTS: The final models predicting low 6-thioguanine levels and nonadherence had area under the curve, 0.87 and 0.94; sensitivity, 0.81 and 0.82; specificity, 0.80 and 86; and distance, 0.31 and 0.21, respectively, when applied on the testing part of the dataset. When the final model for prediction of 6-thioguanine values was applied on testing dataset, a root-mean-square error of 110 was obtained. CONCLUSIONS: Using easily obtained laboratory parameters, we constructed a model with sufficient accuracy to predict patients with low 6-thioguanine levels and a model for prediction of AZA treatment nonadherence (web applications: https://hradskyo.shinyapps.io/6TG_prediction/ and https://hradskyo.shinyapps.io/Non_adherence/).

• MeSH
• adherence k farmakoterapii * MeSH
• biologické modely MeSH
• dítě MeSH
• erytrocyty metabolismus   MeSH
• idiopatické střevní záněty krev   farmakoterapie   metabolismus   MeSH
• imunosupresiva aplikace a dávkování   farmakokinetika   terapeutické užití   MeSH
• lidé MeSH
• merkaptopurin aplikace a dávkování   analogy a deriváty   farmakokinetika   terapeutické užití   MeSH
• mladiství MeSH
• monitorování léčiv MeSH
• plocha pod křivkou MeSH
• prediktivní hodnota testů MeSH
• senzitivita a specificita MeSH
• thioguanin metabolismus   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• hodnotící studie MeSH
• práce podpořená grantem MeSH

• MeSH
• biologické markery chemie   krev   MeSH
• C-reaktivní protein analýza   MeSH
• feces chemie   MeSH
• idiopatické střevní záněty * krev   terapie   MeSH
• leukocytární L1-antigenní komplex analýza   MeSH
• lidé MeSH
• metody pro podporu rozhodování MeSH
• prediktivní hodnota testů MeSH
• sekundární prevence metody   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• novinové články MeSH

• MeSH
• biologické markery analýza   MeSH
• C-reaktivní protein analýza   MeSH
• Crohnova nemoc krev   patologie   MeSH
• feces chemie   MeSH
• idiopatické střevní záněty * krev   patologie   MeSH
• leukocytární L1-antigenní komplex analýza   MeSH
• lidé MeSH
• reakce akutní fáze imunologie   krev   MeSH
• ulcerózní kolitida krev   patologie   MeSH
• zánět imunologie   krev   MeSH
• Check Tag
• lidé MeSH

INTRODUCTION: The aim of our study was to assess association of serum S100A4 protein with ulcerative colitis (UC) and Crohn's disease (CD). METHODS: Study included 118 subjects: 93 patients with CD, 16 with UC and 9 controls. In CD group, 20/93 patients had B1 phenotype, 19/93 B2, 20/93 B3 and 34/93 B2 + B3. L1 involvement was present in 15/93, L2 in 14/93 and L3 in 64/93 patients. Serum S100A4 concentration was investigated in peripheral venous blood samples by means of ELISA. RESULTS: Serum S100A4 was significantly higher in UC (158.6 ± 56.2 ng/mL), p = 0.019 and in CD (154.4 ± 52.1 ng/mL), p = 0.007 compared to controls (104.8 ± 40.5 ng/mL). No difference in S100A4 was revealed between UC and CD, p > 0.05. Serum S100A4 in each CD subgroup (according to behaviour) was significantly higher compared to controls, p < 0.05. Serum S100A4 was significantly higher in L2 (144.6 ± 44.2 ng/mL), p = 0.041 and in L3 (163.0 ± 52.8 ng/mL), p = 0.002 compared to controls and in L3 compared to L1 (126.9 ± 47.6 ng/mL), p = 0.017. CONCLUSION: Association of serum S100A4 protein with UC and CD was confirmed. In CD, disease behaviour did not influence serum concentration of S100A4 protein. In CD, higher levels of serum S100A4 were observed in patients with ileo-colonic and colonic involvement compared to those with isolated small bowel involvement.

• MeSH
• biologické markery krev   MeSH
• dospělí MeSH
• idiopatické střevní záněty krev   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• prospektivní studie MeSH
• S100 kalcium vázající protein A4 krev   MeSH
• senioři MeSH
• studie případů a kontrol MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH